MedTrace Logo

Bevacizumab Intravitreal for Myopic Choroidal Neovascularization

NCT00797992 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2008-11-25

No results posted yet for this study

Summary

To evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary to pathologic myopia (PM-CNV).

Conditions

  • Myopic Choroidal Neovascularization

Interventions

DRUG

Injection

Intravitreal injection of 1.25 mg bevacizumab

Sponsors & Collaborators

  • Instituto de Olhos de Goiania

    lead OTHER

Principal Investigators

  • Joao J Nassaralla, PhD · Instituto de Olhos de Goiania

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00797992 on ClinicalTrials.gov